<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="378">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348656</url>
  </required_header>
  <id_info>
    <org_study_id>CONCOR-1</org_study_id>
    <nct_id>NCT04348656</nct_id>
  </id_info>
  <brief_title>CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)</brief_title>
  <acronym>CONCOR-1</acronym>
  <official_title>A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Blood Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Héma-Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Cornell Medicine/New York-Presbyterian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Blood Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently no treatment available for COVID-19, the acute respiratory illness caused
      by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19
      that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA
      approved the use of convalescent plasma under the emergency investigational new drug (eIND)
      category. Randomized trials are needed to determine the efficacy and safety of COVID-19
      convalescent plasma for acute COVID-19 infection.

      The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19
      convalescent plasma to adult patients admitted to hospital with COVID-19 infection at
      decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19.

      It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma
      early in their clinical course will reduce the risk of death, and that other outcomes will be
      improved including risk of intubation, and length of ICU and hospital stay.

      This pan-Canadian clinical trial has the potential to improve patient outcomes and reduce the
      burden on health care resources including reducing the need for ICU beds and ventilators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Problem to be addressed: In December 2019, the Wuhan Municipal Health Committee (Wuhan,
      China) identified an outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was
      quickly identified in some of these patients.This novel coronavirus has been designated
      SARS-CoV-2, and the disease caused by this virus has been designated COVID-19.Outbreak
      forecasting and mathematical modelling suggest that these numbers will continue to rise [1]
      in many countries over the coming weeks to months.Global efforts to evaluate novel antivirals
      and therapeutic strategies to treat COVID-19 have intensified. There is an urgent public
      health need for rapid development of novel interventions. At present, there is no specific
      antiviral therapy for coronavirus infections.

      Passive immunization:Passive immunization consists in the transfer of antibodies from
      immunized donor to non-immunized individual in order to transfer transient protection against
      an infective agent. A physiological example of passive immunization is the transfer of
      maternal IgG antibodies to the foetus through the placenta to confer humoral protection to
      newborns in the first years of life. Passive immunization differs from active immunization in
      which the patient develops their own immune response following contact with the infective
      agent or vaccine.

      Known potential risks and benefits: There is a theoretical risk of antibody-dependent
      enhancement of infection (ADE) through which virus targeted by non-neutralizing antibodies
      gain entry into macrophages. Another theoretical risk is that antibody administration to
      those exposed to SARS-CoV-2 may avoid disease but modify the immune response such that those
      individuals mount attenuated immune responses, which would leave them vulnerable to
      subsequent re-infection. Finally, there are risks associated with any transfusion of plasma
      including transmission of blood transmitted viruses (e.g. HIV, HBV, HCV, etc.), allergic
      transfusion reactions, including anaphylaxis, febrile non hemolytic transfusion reaction,
      transfusion related acute lung injury (TRALI), transfusion associated cardiac overload
      (TACO), and hemolysis should ABO incompatible plasma be administered. Potential benefits of
      COVID-19 convalescent plasma include improved survival, improvement in symptoms, decreased
      risk in intubation for mechanical ventilation, decrease risk of intensive care unit (ICU)
      admission, shortened hospitalization time and suppression of viral load.

      Mechanism of action: Transfusion of apheresis frozen plasma (AFP) from COVID-19 convalescent
      patients allows the transfer of donor neutralizing antibodies directed against SARS-CoV2
      antigens to the recipient, thus allowing the generation of passive immunization. Naturally
      produced human antibody are polyclonal, meaning they are directed against a variety of
      different viral antigens and epitopes allowing for a general neutralizing effect against the
      virus rather than focussing on a specific target. Administration of convalescent plasma has
      been associated with rapid decrease in viral load. It is also possible that passive
      immunization contributes to improved cell-mediated immunity by favoring the phagocytosis and
      presentation of viral antigens to host T cells.

      Participant recruitment:Only hospitalized COVID-19 patients are eligible so recruitment
      efforts will be focused on identified consecutive patients admitted to hospital with acute
      COVID-19 infection. No other external recruitment efforts are planned. At each participating
      hospital, a process for identifying patients with COVID-19 will be established.

      Donor recruitment for Canadian sites: Recovered COVID-19 patients will be identified as
      potential donors in collaboration with provincial public health services, local health
      authorities, and individual co-investigators involved in the study. Potential donors may also
      be recruiting following self-identification on the routine donor questionnaire or through
      social media. They will be contacted by phone and invited to participate in the program as
      potential donors. After obtaining verbal consent and reviewing donor selection criteria,
      eligible participants will be directed to a Héma-Québec collection or Canadian Blood Services
      apheresis collection site in their area to donate.

      Criteria for donors: All donors will need to meet the criteria set forth in the Manual of
      donor selection criteria in use at Héma-Québec or Canadian Blood ServicesIn addition, donors
      will require:

        -  Prior diagnosis of COVID-19 documented by a PCR test at time of infection or by positive
           anti-SARS-CoV-2 serology following infection

        -  Male donors, or female donors with no pregnancy history or with negative anti-HLA
           antibodies

        -  At least 6 days since last plasma donation

        -  Provided informed consent

        -  A complete resolution of symptoms at least 14 days prior to donation

      Donor recruitment for United States sites: Recovered COVID-19 patients are being recruited
      through the New York Blood Center and Weill Cornell Medicine in separate protocols. Potential
      donors can self-refer via websites but also be referred by physicians or identified via the
      medical record system. Only donors with laboratory-confirmed history of COVID-19 will be
      screened. After providing consent and reviewing FDA and NYBC donor eligibility criteria,
      donors are screened for the presences of SARS-CoV-2 virus in the nasopharynx if screening
      within 14 days of complete resolution in accordance with current FDA guidance. Criteria for
      donation are subject to change based on future revision of FDA guidance. Those found to be
      eligible will be referred to NYBC for donation.

      Criteria for donors:

        -  Provision of informed consent

        -  Aged 18 to 70 years. Donors are not longer eligible after their 71st birthday.

        -  Documented molecular diagnosis of SARS-CoV-2 by RT-PCR by nasopharyngeal swab,
           oropharyngeal swab, or sputum or detection of anti-SARS-CoV-2 IgG in serum.

        -  Complete resolution of COVID-19 symptoms at least 14 days prior to donation

        -  Not currently pregnant or pregnant within 6 weeks by self-report

        -  Male donors, or females with no pregnancy history or with negative anti-HLA antibodies

        -  Meets blood donor criteria specified by NYBC, which is consistent with FDA regulations.

      Donors will be allowed to donate every 7 days. The following information will be collection
      from donors: ABO group, sex, age, date of onset of symptoms (when available), date of
      resolution of symptoms (when available), CCP collection date(s).

      Randomization procedures: Patients will be randomized in a 2:1 ratio (convalescent plasma vs
      standard of care). Patients will be randomized using a secure, concealed, computer-generated,
      web-accessed randomization sequence. Randomization will be stratified by centre and age (&lt;60
      and ≥ 60 years). Within each stratum, variable permuted block sized will be used. This
      approach will ensure that concealment of the treatment sequence is maintained.

      Duration of follow-up: Subjects will be followed daily until hospital discharge or death.
      Patients discharged from hospital before Day 30 will be contacted by telephone on Day 30 ± 3
      days to ascertain any AEs, vital status (dead/alive), hospital readmission and need for
      mechanical ventilation after discharge. Patients discharged from hospital will be contacted
      at Day 90+/- 7 days to determine vital status. Patients with a prolonged hospital admission
      will be censored at Day 90. The local study coordinator will collect all study data and
      record the data in the electronic CRF or paper CRF as per study procedures for each site.

      Duration of study: For an individual subject, the study ends 90 days after randomization. The
      overall study will end when the last randomized subject has completed 90 day follow-up. We
      estimate that all patient will be enrolled in a period of 6 months, data on the primary
      endpoint will be available 30 days after last patient enrollment and data on all secondary
      endpoints will be available after 90-day from last patient enrollment.

      Sample size considerations: Assuming a baseline risk of intubation or death of 30% in
      hospitalized patients with standard of care, a sample size of 1200 (800 in the convalescent
      plasma arm, and 400 in the standard of care arm) would provide 80% power to detect a relative
      risk reduction of 25% with convalescent plasma therapy using a 2-tailed test at level α =
      0.05 and a 2:1 randomization.

      Interim analysis: A single interim analysis is planned when the primary outcome (intubation
      or mortality at 30 days) is available for 50% of the target sample. An O'Brien-Fleming
      stopping rule will be used at that time, but treated as a guideline, so there is minimal
      impact on the threshold for statistical significance for the final significance test of the
      primary outcome. A DSMB will monitor ongoing results to ensure patient well-being and safety
      as well as study integrity. The DSMB will be asked to recommend early termination or
      modification only when there is clear and substantial evidence of a treatment difference.

      Final analysis plan: The primary analysis will be based on the intention-to-treat population
      which will include data from all individuals who have been randomized. Outcomes will be
      attributed to the arm to which individuals were randomized irrespective of whether they
      received the planned intervention (e.g. plasma from a convalescent COVID-19 donor).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation or death in hospital</measure>
    <time_frame>Day 30</time_frame>
    <description>Endpoint of the need for intubation or patient death in hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Intubation</measure>
    <time_frame>Day 30</time_frame>
    <description>Endpoint of the need for intubation before 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intubation</measure>
    <time_frame>Day 30</time_frame>
    <description>Time in hours to intubation from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>Day 30</time_frame>
    <description>Endpoint of the number of days off ventilator at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital death</measure>
    <time_frame>90 days</time_frame>
    <description>In-hospital death censored at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to in-hospital death</measure>
    <time_frame>Day 90</time_frame>
    <description>Time to in-hospital death at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Death at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit (ICU)</measure>
    <time_frame>Day 30</time_frame>
    <description>Date of intensive care unit admission (first date and total number of days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>Day 30</time_frame>
    <description>Date of hospital admission (first date and total number of days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for extracorpeal membrane oxygenation (ECMO)</measure>
    <time_frame>Day 30</time_frame>
    <description>First date on ECMO and total number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>Day 30</time_frame>
    <description>Need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of myocarditis</measure>
    <time_frame>Day 30</time_frame>
    <description>New myocarditis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>Day 30</time_frame>
    <description>Transfusion-associated adverse events, Grade 3 and 4 serious adverse events, and cumulative incidence of Grade 3 and 4 adverse events and serious adverse events (using medDRA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCP transfusion-associated adverse events (AE)</measure>
    <time_frame>30 days</time_frame>
    <description>CCP transfusion-associated adverse events (AE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>~500 mL ABO compatible convalescent apheresis plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treated as per institutional standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.</description>
    <arm_group_label>Convalescent plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥16 years old (&gt;18 years of age in the United States)

          -  Admitted to hospital with confirmed COVID-19 respiratory illness

          -  Receiving supplemental oxygen

          -  500 mL of ABO compatible convalescent plasma is available

        Exclusion Criteria:

          -  Onset of symptoms &gt;12 days prior to randomization

          -  Intubated or plan in place for intubation

          -  Plasma is contraindicated (e.g. history of anaphylaxis from transfusion)

          -  Decision in place for no active treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald M Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donald M Arnold, MD</last_name>
    <phone>9055259140</phone>
    <phone_ext>28603</phone_ext>
    <email>arnold@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin B Jamula, MSc.</last_name>
    <phone>9055259140</phone>
    <phone_ext>21845</phone_ext>
    <email>jamulae@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brooklyn Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Romero</last_name>
      <email>tar7017@nyp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lower Manhattan Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lewis</last_name>
      <email>mel2025@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine Arar</last_name>
      <email>cea4002@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter Lougheed Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Robinson</last_name>
      <email>Traci.Robinson@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Robinson</last_name>
      <email>Traci.Robinson@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rockyview General Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Robinson</last_name>
      <email>Traci.Robinson@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Robertson</last_name>
      <email>Kimberly.Robertson2@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sturgeon Community Hospital</name>
      <address>
        <city>St. Albert</city>
        <state>Alberta</state>
        <zip>T8N 6C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Robertson</last_name>
      <email>Kimberly.Robertson2@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorell Gantioqui</last_name>
      <email>jorell.gantioqui@vch.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Jubilee Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Roarty</last_name>
      <email>Tracey.Roarty@VIHA.CA</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria General Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8Z 6R5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Roarty</last_name>
      <email>Tracey.Roarty@VIHA.CA</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Ajax Pickering</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 2J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Robinson</last_name>
      <email>horobinson@lh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Lucier</last_name>
      <email>lucierkj@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>France Clarke</last_name>
      <email>clarkef@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayna Jeromin</last_name>
      <email>jayna.jeromin@grhosp.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayna Jeromin</last_name>
      <email>Jayna.Jeromin@grhosp.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eni Nano</last_name>
      <email>Eni.Nano@sjhc.london.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eni Nano</last_name>
      <email>Eni.Nano@sjhc.london.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Markham Stouffville Hospital</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 7P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edeliza Mendoza</last_name>
      <email>emendoza@msh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trillium Health Partners - Mississauga Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Romano</last_name>
      <email>martin.romano@thp.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trillium Health Partners - Credit Valley</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Romano</last_name>
      <email>martin.romano@thp.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Schlag</last_name>
      <email>Maria.Schlag@nygh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Robinson</last_name>
      <email>horobinson@lh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Carr</last_name>
      <email>hcarr@ohri.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital - Civic Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Carr</last_name>
      <email>hcarr@ohri.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queensway Carleton Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2H 8P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Walcer</last_name>
      <email>mwalcer@qch.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scarborough Health Network, Centenary Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1E 4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Wang</last_name>
      <email>Jianmin.Wang@nygh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scarborough Health Network, General Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Wang</last_name>
      <email>Jianmin.Wang@nygh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scarborough Health Network, Birchmount Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1W 3W3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Wang</last_name>
      <email>Jianmin.Wang@nygh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amie Kron</last_name>
      <email>amie.kron@sunnybrook.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unity Health St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Lindsay</last_name>
      <email>Daniel.Lindsay@unityhealth.to</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sinai Health System</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samia Saeed</last_name>
      <email>Samia.Saeed@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samia Saeed</last_name>
      <email>Samia.Saeed@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samia Saeed</last_name>
      <email>Samia.Saeed@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unity Health, St. Joseph's Health Care Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Lindsay</last_name>
      <email>Daniel.Lindsay@unityhealth.to</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Hospital - Metropolitan Campus</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista Naccarato</last_name>
      <email>Krista.Naccarato@wrh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Hospital - Ouellette Campus</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N9A 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista Naccarato</last_name>
      <email>Krista.Naccarato@wrh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Cité-de-la-Santé</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange Tremblay</last_name>
      <email>stremblay.csssl@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles-Le Moyne</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrée-Anne Turcotte</last_name>
      <email>andree-anne.turcotte.cisssmc16@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Hospital of Lévis</name>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estel Duquet-Deblois</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie T Lu</last_name>
      <email>jtlu.hmr@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Rioux-Masse</last_name>
      <email>benjamin.rioux-masse.chum@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine Auclair</last_name>
      <email>marie.christine.auclair@recherche-ste-justine.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Lambert</last_name>
      <email>clambert@jgh.mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karène Proulx-Boucher</last_name>
      <email>karene.proulx-boucher@muhc.mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Coeur de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anatolie Duca</last_name>
      <email>anatolie.duca@crhsc.rtss.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Québec - Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bellemare</last_name>
      <email>David.Bellemare@crchudequebec.ulaval.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de cardiologie et pneumologie de Québec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Roy</last_name>
      <email>annie.roy@criucpq.ulaval.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional de St-Jérôme</name>
      <address>
        <city>Saint-Jérôme</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick Sardin</last_name>
      <email>yanick.s.laframboise.cissslau@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ciussse De L'Estrie CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Lacasse</last_name>
      <email>robert.lacasse.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier affilié universitaire régional de Trois-Rivières</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Tapps</last_name>
      <email>danielle_tapps@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Gryzb</last_name>
      <email>Karolina.Grzyb@saskhealthauthority.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Gryzb</last_name>
      <email>Karolina.Grzyb@saskhealthauthority.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7M 0Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Hodgson</last_name>
      <email>neh798@usask.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Hodgson</last_name>
      <email>neh798@usask.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 Feb 29;395(10225):689-697. doi: 10.1016/S0140-6736(20)30260-9. Epub 2020 Jan 31. Erratum in: Lancet. 2020 Feb 4;:.</citation>
    <PMID>32014114</PMID>
  </reference>
  <reference>
    <citation>2. FDA USFDA. Investigational COVID-19 Convalescent Plasma - Emergency INDs [Web]. 2020 [Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds accessed March 26th 2020.</citation>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Convalescent plasma</keyword>
  <keyword>Transfusion</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Passive immunization</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

